Commentary: Evaluation of Models of Parkinson's Disease by Patricia Muñoz et al.
GENERAL COMMENTARY
published: 19 April 2016
doi: 10.3389/fnins.2016.00161
Frontiers in Neuroscience | www.frontiersin.org 1 April 2016 | Volume 10 | Article 161
Edited by:
Mark R. Cookson,










This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 09 February 2016
Accepted: 29 March 2016
Published: 19 April 2016
Citation:
Muñoz P, Paris I and Segura-Aguilar J
(2016) Commentary: Evaluation of
Models of Parkinson’s Disease.
Front. Neurosci. 10:161.
doi: 10.3389/fnins.2016.00161
Commentary: Evaluation of Models
of Parkinson’s Disease
Patricia Muñoz 1, Irmgard Paris 1, 2 and Juan Segura-Aguilar 1*
1Molecular and Clinical Pharmacology, Faculty of Medicine, University of Chile, Santiago, Chile, 2Departamento de Ciencia
Básicas, Facultad de Ciencias, Universidad Santo Tomas, Viña del Mar, Chile
Keywords: preclinical models, Parkinson therapy, aminochrome, dopamine, neurodegeneration, MPTP,
6-hydroxidopamine, L-dopa
A commentary on
Evaluation of Models of Parkinson’s Disease
by Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., and Khurana, S. (2016). Front. Neurosci. 9:503.
doi: 10.3389/fnins.2015.00503
This publication is a review on the preclinical model used today for Parkinson’s disease that take
in consideration both preclinical model based on neurotoxin or mutations associated to familial
Parkinson’s disease (PD). The aim of this commentary is to introduce a new point of view about
the actual preclinical models, open discussion, and propose a new preclinical model. The use of
correct preclinical model to study the mechanisms and to test possible new therapies is essential to
obtain successful results and new therapies. The discovery that dopamine loss was associated to the
disease was essential to the use of L-dopa in Parkinson’s disease therapy. L-dopa has been the most
used drug in the disease treatment during near five decades despite the severe side effects observed
after 4–6 years treatment (Segura-Aguilar et al., 2015). The actual treatment of the disease is based
on dopaminergic and anti-cholinergics compounds. The scientific community and pharmaceutical
companies have failed to find new drugs to halt the progression of the disease and the worst is that
the focus to find new therapies is centered on drugs to alleviate the side effects of L-dopa such as
dyskinesia. There are a long list of successful preclinical studies that have failed to translate these
positive results to clinical studies and new therapies, for example pioglitazone, topiramate, GDNF,
creatine, ubiquinone, cognane, mitoquinone, etc. (Athauda and Foltynie, 2015; Lindholm et al.,
2015; Olanow et al., 2015; Park and Stacy, 2015).
The question is why successful results in preclinical studies cannot be translated to clinical
studies? In our opinion (i) The preclinical models based on exogenous neurotoxins such as
6-hydroxidopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been very
useful and valuable tools to study mechanisms. However, these preclinical models do not reflect
what happen in the disease and therefore, these models are worthless to develop new drugs. One
of the features of these exogenous neurotoxins is that all induce a rapid and extensive degeneration
in animals. In humans MPTP induced a severe Parkinsonism in just 3 days after the use of a
synthetic illicit drugs contaminated with MPTP. The rapid and extensive degeneration induced
by exogenous drugs contrast with the very slow degeneration in Parkinson where the take years
to develop motor symptoms. How we can translate results from preclinical to clinical studies
when the mode of action is complete different. The exogenous drugs are killing all possible
dopaminergic neurons which have affinity, suggesting that the very slow degeneration observed in
Parkinson’s disease must be dependent on an endogenous neurotoxin. It has been reported a new
preclinical model based on β-sitosterol β-D-glucoside that triggers the progressive development
of Parkinsonism, exhibiting olfactory deficit in the absence of significant cell loss or locomotor
deficits. The question is whether this preclinical model can be used to develop new drugs in PD
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(Van Kampen et al., 2015); and (ii) the molecular mechanism(s)
responsible for the loss of dopaminergic neurons containing
neuromelanin remain unknown. The discovery of genes
associated a familial form of Parkinson’s disease do not
explain what happen in the sporadic form of the disease
but they resulted in an enormous input in basic research
in order to understand the role of these proteins in the
disease. In general there is an agreement in the scientific
community that the neurodegeneration of dopaminergic neurons
containing neuromelanin involves mitochondrial dysfunction,
formation of neurotoxic alpha-synuclein oligomers, protein
degradation dysfunction of both lysosomal and proteasomal
systems, oxidative stress, neuroinflammation, and endoplasmic
reticulum stress (Segura-Aguilar et al., 2014).
We have proposed that aminochrome can be used as a
preclinical model for Parkinson disease (Segura-Aguilar et al.,
2014, 2015). Unilateral injection of aminochrome into rat
striatum induces a progressive contralateral behavior without loss
of nigrostriatal dopaminergic neurons. Instead, aminochrome
induces neuronal dysfunction of dopaminergic neurons since
the level of dopamine significantly decrease while GABA level
FIGURE 1 | Astrocytes protect dopaminergic neurons against aminochrome neurotoxicity. Astrocytes secrete GSTM2 which is internalized by dopaminergic
neurons in order to increase their protection against aminochrome. Dopamine oxidation to neuromelanin is a harmless pathway due to the presence of DT-diaphorase
and GSTM2 that prevent aminochrome-dependent neurotoxicity by inhibiting the formation of alpha-synuclein (SNCA) neurotoxic oligomers, mitochondrial
dysfunction, oxidative stress, autophagy, and proteasome dysfunction and endoplasmic reticulum stress.
significantly increase, generating a neurotransmitter imbalance.
The decrease in dopamine release without degeneration of
nigrostriatal neurons can be explained by the fact that
aminochrome induces mitochondrial dysfunction, significant
decrease of ATP level in the striatum and in the number
of synaptic vesicles (Herrera et al., 2016). Aminochrome is
one of the o-quinones formed during dopamine oxidation to
neuromelanin and it has been found to induce mitochondrial
dysfunction (Aguirre et al., 2012), formation of neurotoxic
alpha-synuclein oligomers (Muñoz et al., 2015), oxidative stress
(Arriagada et al., 2004), dysfunction of protein degradation
of both proteasomal (Zafar et al., 2006) and lisosomal
(Huenchuguala et al., 2014) systems, endoplasmic reticulum
stress (Xiong et al., 2014).
Aminochrome is the most stable o-quinone formed during
dopamine oxidation and it participates on both neurotoxic and
neuroprotective reactions. Aminochrome is neurotoxic when it
forms adducts with proteins or it is one-electron reduced by
flavoenzymes which catalyzes one electron transfer. However,
there are two enzymes that prevent aminochrome neurotoxicity
(Figure 1): (i) DT-diaphorase prevents aminochrome-induced
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cell death, mitochondrial dysfunction, oxidative stress, protein
degradation dysfunction of both proteasomal and lysosomal
systems, and formation of alpha-synuclein neurotoxic oligomers
(Segura-Aguilar et al., 2014, 2015); and (ii) glutathione
transferase M2-2 (GSTM2) catalyzes the GSH conjugation of
both aminochrome and its precursor dopamine o-quinone and
it is expressed only in astrocytes. GSTM2 prevent aminochrome
toxicity in astrocytes when dopamine takes up from intersynaptic
space after neurotransmission and oxidizes to aminochrome
in the astrocytes. Interestingly, astrocytes secrete GSTM2 into
conditioned medium and dopaminergic model neurons take
up GSTM2 and prevent aminochrome-induced neurotoxicity
in these neurons (Cuevas et al., 2015). Therefore, GSTM2
play a protective role against aminochrome both in astrocytes
and dopaminergic neurons. The protective role of both DT-
diaphorase and GSTM2 against aminochrome can explain why
dopamine oxidation to neuromelanin is not normally a harmful
pathway. The use of animals with DT-diaphorase or GSTM2
knockout injected with aminochrome maybe a new preclinical
to study both PD mechanisms and to develop new PD drugs.
In conclusion, the failure to translate successful result from
preclinical to clinical studies and develop new pharmacological
therapies will continue until we found a preclinical model that
use an endogenous neurotoxin which is involved in the disease
development.
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